14 research outputs found
MSKCC Quality Assessment (QA) monitoring program for potentially harmful chemotherapy orders
No full textMSKCC Quality Assessment (QA) monitoring program for potentially harmful chemotherapy orders
No full textPathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study.
No full textCorrelative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC).
No full textSequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy
No full textPhase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
No full text5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women With High-Risk Node-Positive Breast Cancer: A Phase II Study
No full textTBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC).
No full textAdjuvant radiotherapy for breast cancer as a risk factor for the development of lung cancer
No full textPhase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
No full text
